IMAB (NASDAQ:IMAB) Q2 2020 Earnings Conference Call - Final Transcript
Aug 31, 2020 • 08:00 am ET
Good day, ladies and gentlemen, thank you for standing by, and welcome to the I-Mab 2020 Interim Financial Results and Business Update Conference Call. [Operator Instructions].
It is now my pleasure to turn the call over to Jielun Zhu, I-Mab's Chief Financial Officer and Director. Please go ahead, Mr. Zhu.
Thank you, Rachel. Welcome to the I-Mab 2020 interim financial results and business update conference call. Earlier this evening, we issued a press release providing a review of our financial results for the six months ended June 30, 2020, as well as an overview of our recent corporate highlights, and upcoming milestones. The press release can be accessed on the Investors portion of our corporate website, ir.i-mabbiopharma.com.com.
Joining me today on the call from I-Mab senior management team are Dr. Jingwu Zang, our Founder, Honorary Chairman and Director. Dr. Joan Shen, our Chief Executive Officer and Director; and Mr. Yifei Zhu, our Chief Commercial Officer. Mr. Zhu recently joined I-Mab and will be driving our commercialization efforts in preparation of our first product launch in China.
Dr. Zang will provide a high level overview of our recent achievements and upcoming milestones, and Dr. Shen will comment on the status of our key development programs in greater detail. I will then provide a brief summary of our financial results for the six months ended June 30, 2020, before we turn the call back over to the operator, so we may take your questions.
Please note, the discussion today will contain forward-looking statements relating to the company's future performance and are intended to qualify for the Safe Harbor from liability, as established by the U.S. Private Securities Litigation Reform Act. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions and other factors. Some of these risks are beyond the company's control, and could cause actual results to differ materially from those mentioned in today's press release, and this discussion. A general discussion of the risk factors that could affect I-Mab's business and financial results is included in certain filings of the company, with the Securities and Exchange Commission. The company does not undertake any obligation to update this forward-looking information, except as required by law. During today's call, we will also discuss certain non-GAAP financial measures, for comparison purposes only. For a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial measures, please see the financial results news release issued earlier today.
Now I will turn the call over to Dr. Jingwu Zang, our Founder, Honorary Chairman and Director, Dr. Zang, Please go ahead.
Jingwu Zhang Zang
Thank you, Jielun. Thank you all for joining us today. I'm very pleased to welcome all of you to our 2020 interim financial results and business update conference call. This is an exciting time for I-Mab. We have made substantial progress in pipeline development, as well as corporate development over the last several months, and we are on our way to becoming a leading, fully integrated, global